文献速递支持与姑息治疗

肿瘤重症患者ICU收治与治疗终点的抉择

[The option of critical patients with cancer for ICU].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2018-01-01

随着肿瘤成为慢性病,带瘤生存患者增多,ICU需求增长并挑战传统理念。文章提出肿瘤重症患者的ICU抉择包括收治抉择与治疗终点抉择:应拓宽收治标准,初治患者享有与非肿瘤患者等同的ICU治疗,疗效未知者可行ICU试验性治疗;试验性治疗3~6天后若病情无改善,应召开跨学科会议讨论生命结束方式,转向姑息与临终关怀。

要点

  • 建议拓宽肿瘤患者ICU收治标准。
  • 初治肿瘤患者ICU治疗等同非肿瘤患者。
  • 疗效未知者可予ICU试验性治疗,包括抢救性化疗。

核心结论

  • 肿瘤重症患者的ICU抉择应包括收治抉择与治疗终点抉择两方面。
  • 将伦理学、姑息治疗和重症监护治疗合理有效整合可能是未来肿瘤专科ICU的发展方向之一。

主要发现

  • 随着诊断和治疗水平提高,肿瘤已成为慢性疾病,带瘤生存患者大量存在。
  • 这一变化导致对ICU需求增长,也引发对ICU传统治疗理念的挑战。

关键数值与推荐

  • 初治肿瘤患者应享有与非肿瘤患者等同的ICU治疗。
  • 治疗效果未知的患者应获得ICU试验性治疗机会,给予不限定力度的有创治疗,包括介入、抢救性化疗等抗肿瘤治疗。
  • ICU试验性治疗3~6天后,通过序贯性器官功能评分等指标评估病情仍无改善,可召开包括伦理指导在内的跨学科会议,与患者家属讨论生命结束方式。

临床怎么用

  • 对初治肿瘤患者按与非肿瘤患者等同的full-code状态进行ICU治疗。
  • 对疗效未知或未确定者允许ICU试验性治疗,包括不限定力度的有创支持和抢救性化疗。
  • ICU试验性治疗3~6天后若SOFA评分显示临床恶化且无可用治疗选择,与家属讨论生命结束方式,治疗目标转向临终关怀。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

With the improvement of diagnosis and treatment, tumor has become a chronic disease, and an increasing number of older patients will live with tumors. This change has led to an increase in demand for intensive care unit (ICU) and a challenge to the traditional ICU treatment concept. The option of ICU consists of two parts. The first is the option for admission. Since classic predictors of mortality are no longer relevant, we suggest broadening the criteria for ICU admission. Patients during the first course of cancer therapies should be treated with a full-code status similar to that of other patients without malignancy. Patients whose clinical response to therapy was not available or undetermined should be allowed an ICU trial that consists of unlimited invasive support, including anti-cancer therapies such as ambulatory chemotherapy. Do everything that can be done to save the patients who might benefit from ICU treatment. The second is the option of therapeutic end point. An interdisciplinary meeting, including an ethics consultation, should be held after 3-6 days'ICU trial to make end-of-life decisions with relatives of patients if the SOFA score shows clinical deterioration with no available therapeutic options. The treatment goals should shift from curative or supportive therapies to end-of-life care. we could integrate hospice and palliative care with intensive care more effectively and efficiently. That would be the future of oncological ICUs. 随着诊断和治疗水平的提高,肿瘤已经成为一种慢性疾病,带瘤生存患者大量存在。这种变化,既导致了对重症监护治疗病房(ICU)需求的增长,也引发了对ICU传统治疗理念的挑战。对于肿瘤重症患者,其ICU抉择包括两方面内容:首先是收入ICU的抉择。需要拓宽ICU的收入标准,除了初治肿瘤患者享有与非肿瘤患者等同的ICU治疗外,治疗效果未知的患者也应获得ICU试验性治疗的机会,给予不限定力度的有创治疗,包括介入、抢救性化疗等抗肿瘤治疗,尽量挽救可通过ICU治疗获益的患者。其次是治疗终点抉择。ICU试验性治疗3~6 d后,通过序贯性器官功能评分等指标评估病情仍无改善,可召开包括伦理指导在内的跨学科会议,与患者家属讨论生命结束方式,治疗方向及时向姑息治疗和临终关怀转化。将伦理学、姑息治疗和重症监护治疗合理有效整合,可能是未来肿瘤专科ICU的发展方向之一。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Xia R, Wang DH. [The option of critical patients with cancer for ICU]. Zhonghua Zhong Liu Za Zhi. 2018. PMID: 29502379. doi:10.3760/cma.j.issn.0253-3766.2018.02.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。